## University of Texas at Tyler

# Scholar Works at UT Tyler

**MSN Capstone Projects** 

Nursing

Spring 4-24-2024

# BRAIN MATTERS: COGNITIVE-BEHAVIORAL THERAPY AND ANTIDEPRESSANTS FOR POST-STROKE DEPRESSION

Lindsey Anne Smith University of Texas at Tyler, lsmith57@patriots.uttyler.edu

Follow this and additional works at: https://scholarworks.uttyler.edu/nursing\_msn



Part of the Nursing Commons

#### **Recommended Citation**

Smith, Lindsey Anne, "BRAIN MATTERS: COGNITIVE-BEHAVIORAL THERAPY AND ANTIDEPRESSANTS FOR POST-STROKE DEPRESSION" (2024). MSN Capstone Projects. Paper 324. http://hdl.handle.net/10950/4663

This MSN Capstone Project is brought to you for free and open access by the Nursing at Scholar Works at UT Tyler. It has been accepted for inclusion in MSN Capstone Projects by an authorized administrator of Scholar Works at UT Tyler. For more information, please contact tgullings@uttyler.edu.

# Brain Matters: Cognitive-Behavioral Therapy and Antidepressants for Post-Stroke Depression: A Benchmark Project

Lindsey A. Smith, BSN, RN, SCRN, CCRN

The University of Texas at Tyler, School of Nursing

For NURS 5382: Capstone

Dr. J. Michelle Nelson

April 22, 2024

# **Contents**

Acknowledgments

**Executive Summary** 

# Implementation and Benchmark Project

- 1. Rationale for the Project
- 2. Literature Synthesis
- 3. Project Stakeholders
- 4. Implementation Plan
- 5. Timetable/Flowchart
- 6. Data Collection Methods
- 7. Evaluation
- 8. Cost/Benefit Analysis
- 9. Discussion of Results

# **Conclusions/Recommendations**

# References

**Appendices** 

## Acknowledgments

I want to thank the incredible professors who have been supportive and encouraging throughout this journey. Their enthusiasm for teaching and investment in my success has meant the world to me. I want to thank God for the blessing of knowledge. My faith has been instrumental in shaping my life, and I would not be where I am today without my faith in Christ. Thank you to my friends, family, and colleagues who have believed in me even when I did not believe in myself. Most of all, I would like to thank my mother. There are not enough words to express the love and gratitude I have for her. When I was brought onto this earth, God gave me the best mom possible. I would not be where I am today had it not been for her. Whenever I would doubt myself, she always told me, "You can do anything, because I believe in you."

### **Executive Summary**

Stroke is the leading cause of death and disability in the United States, and approximately one-third of these patients will develop post-stroke depression, which is associated with higher rates of morbidity and mortality (American Stroke Association, 2022). Even though post-stroke depression is prevalent, it often goes undertreated. The combination of antidepressants and cognitive-behavioral therapy has shown to be an effective method of treating post-stroke depression. There are cognitive-behavioral exercises that nurses can implement, such as group therapy, acceptance therapy, and cognitive retraining, a method of coaching the patient to replace negative thoughts with positive ones (Byun et al., 2021). With the addition of antidepressants prescribed by advanced practice practitioners or physicians, the patients can receive combination therapy. The consequences of not treating post-stroke depression include significant increases in hospitalization costs, poor patient outcomes, and increased length of stay (Lavu et al., 2022; American Stroke Association, 2022). The combination of antidepressants with cognitivebehavioral therapies versus singular treatment with antidepressants alone has shown to be effective in decreasing post-stroke depression symptoms and therefore should be considered as first-line treatment (Starkstein & Hayhow, 2019).

To address the problem of post-stroke depression, the following research question was developed: In post-stroke patients who develop depression, how effective is cognitive-behavioral therapy combined with antidepressants, compared to antidepressants alone, in treating post-stroke depression symptoms, within the first three months post-stroke? Multiple stakeholders such as the bedside nurses will be instrumental in implementing the project in the neurological units and continuing it throughout the rehabilitation phase until the patients are discharged. These patients will receive a combination intervention of cognitive-behavioral therapy and

antidepressants for 12 weeks or until discharge. Results will be measured with the Patient Health Questionnaire (PHQ-9) survey and the Modified Rankin score, which measure depression symptoms and level of functionality. Discharge functionality data gathered from Modified Rankin scores will be analyzed using inferential statistics. The desired results are that these patients have an improvement in emotional status and functional outcomes, decreased length of stay, and a reduction in hospitalization costs.

**BRAIN MATTERS: POST-STROKE DEPRESSION** 

Brain Matters: Cognitive-Behavioral Therapy and Antidepressants for Post-Stroke

Depression: A Benchmark Project

People who suffer from a stroke face many difficult challenges. They may incur long-term hospitalization, significant hospital bills, and life-changing disabilities. This event can lead to the development of post-stroke depression, which further complicates recovery. The goal of this project is to explore ways that post-stroke depression can be mitigated so that stroke sufferers can live a long and meaningful life.

# **Rationale for the Project**

Each year, nearly 800,000 people in the United States suffer from a stroke, costing Americans a staggering \$56 billion per year, and contributing to the leading cause of death and disability in the United States (Centers for Disease Control and Prevention, 2023). The various types of strokes include those caused by a blood clot, intracerebral hemorrhage, or subarachnoid hemorrhage. Among those who suffer from a stroke, approximately 33% of these patients will develop post-stroke depression, which is associated with a greater incidence of poor functional outcomes, morbidity, and mortality (American Stroke Association, 2022). The facility where this project will be implemented is a Comprehensive Stroke Center and is in the top 1,000 out of 6,000 hospitals for treating stroke (U.S. News and World Report, 2023). Since this facility is a top-tier hospital for stroke treatment, they treat approximately 900-1,000 stroke patients per year in the neurological intensive care unit alone, not including the medical-surgical units. This means that a minimum of 300 patients treated each year in this facility will develop post-stroke depression. Morbidity and mortality rates can increase by as much as 90% for stroke patients who develop depression, further contributing to poor functional outcomes, long-term disability, and the incidence of suffering more strokes in the future (Lavu et al., 2019). All too often, only

the immediate physical deficits of a stroke are treated, while neglecting the patients' emotional health. These emotional needs must be addressed so that patients can have the best recovery possible.

# **Literature Synthesis**

Evidence to support the research was collected by performing a systematic literature search across multiple databases. The APA PsycINFO, CINAHL, Cochrane, PubMed, and Google Scholar databases were searched using the keywords from the research question: depression, stroke, cognitive-behavioral therapy, and antidepressants. After a comprehensive review of the literature, twelve articles were chosen that best supported the proposed intervention of cognitive-behavioral therapy combined with antidepressants for post-stroke depression.

Ahrens et al. (2023), Byun et al. (2021), and Van Nimwegen et al. (2023) found that nurses are important in implementing cognitive-behavioral interventions such as group therapy, coping strategies, exercise, cognitive retraining, group acceptance therapy, reminiscence therapy, and goal-setting activities. These activities alone or in combination with antidepressants can be led by nurses to help reduce the rate of post-stroke depression. Byun et al. (2021) and Starkstein & Hayhow (2019) found that nurses and therapists in the rehabilitation setting are vital in implementing cognitive-behavioral interventions. For example, patients given cognitive-behavioral intervention sessions in combination with antidepressants prescribed by a provider had better outcomes several months post-stroke versus those who received a singular treatment. Starkstein & Hayhow (2019) suggested that combination interventions of cognitive-behavioral therapy and antidepressants should be the first-line treatment for post-stroke depression, and in a recent systematic literature review and evaluation of current practice guidelines, Cross et al.

(2023) state that combination therapy of antidepressants and cognitive interventions should be initiated together as quickly as possible after identifying the depression.

Lee et al. (2020) and Xie et al. (2022) found that cognitive-behavioral therapy when combined with antidepressants had a significant impact on the prevalence of post-stroke depression. They noted that cognitive-behavioral therapy should not replace antidepressants but should be used as an adjunct therapy. Withers et al. (2021) and Tao et al. (2022) concluded that combining cognitive-behavioral interventions with antidepressants may be an effective strategy for reducing post-stroke depression, but suggested that the evidence be supported with more research.

Medeiros et al. (2020) and Desai & Sonawane (2019) concluded that post-stroke depression can be managed with early recognition and prompt interventions. The combination of cognitive-behavioral therapy and antidepressants proved to be the most effective treatment strategy for post-stroke depression. Desai & Sonawane (2019) found that although only a small percentage of patients received combination therapy, the ones who did receive it saw a 47% reduction in depression on the Hamilton Depression Rating Scale after eight weeks of therapy. Early detection of post-stroke depression and implementation of combination therapy is crucial to a patient's recovery (Desai & Sonawane, 2019; Sarkar et al., 2021).

# **Project Stakeholders**

The stakeholders involved in the project include patients, bedside nurses, the neurological intensive care unit and neurological step-down unit managers, the Chief Nursing Officer, the Neuroscience Center director/Stroke Coordinator, physicians and advanced practice nurses, physical therapists, nurse educators, and nurse case managers. Approval for the project will first come from the Chief Nursing Officer, and the approval for implementation on the units will be

from the unit managers. The Neuroscience Center director/Stroke Coordinator will be instrumental in keeping the project in sync with current practice guidelines. The bedside nurses are integral in implementing the project, and the physical therapists will assist with functional goals and the Modified Rankin scores. Physicians and advanced practice nurses will prescribe the antidepressants. Nurse educators will assist with HealthStream and in-person education. The case managers will help with post-discharge planning and patient follow-up. Patients are the most important stakeholders because they will be the ones receiving the combination interventions, and their participation is vital to the project's success.

### **Implementation Plan**

The first step of implementation is to obtain approval from the Chief Nursing Officer and the Neuro Institute Director. After receiving their approval, the project will be presented to the neurological intensive care unit and neurological step-down unit managers. After receiving their approval, a meeting will be held with the neurological nurse educator to create depression symptoms recognition and cognitive-behavioral exercise training for the nurses. After creating the education about the planned initiative, it will be posted to each unit's HealthStream education platform. Not all the bedside nurses will be expected to participate. A set number of nurses will be allowed to volunteer to participate in the project. Once these nurses are chosen, they will complete the training and education, and will also be given in-person education sessions on the project and different ways to implement cognitive-behavioral training. The rehabilitation hospital is connected to the inpatient facility, so these nurses will also receive training so that the patients can receive the interventions throughout the entire hospital stay. After educating the nurses, the next step is to obtain buy-in from the attending physicians and neurologists since a physician or advanced practice practitioner will need to order the antidepressant medications. Also, approval

will have to be given by the facility's Internal Review Board since the project requires the addition of new medications and cognitive-behavioral therapies. After submitting for and receiving approval, the project can begin (Office for Human Research Protections, 2018).

After receiving approval, in the first step of implementation, every patient admitted with a diagnosis of a stroke such as ischemic, hemorrhagic, or subarachnoid, will be given a Patient Health Questionnaire (PHQ-9) on admission. A Modified Rankin Scale will also be filled out by a nurse or physical therapist. Patients who score even mildly depressed will begin to receive the combination therapy. The patient's progress will be monitored throughout their stay in the intensive care unit and step-down. This patient's progress will then be monitored throughout the rehabilitation stay, with surveys being filled out at one week, two weeks, four weeks, and six weeks. Once the patient is discharged home from the rehabilitation hospital, a follow-up phone call will be made between 10 and 12 weeks after the initial stroke to monitor the patient's functional and emotional status. The success of the implementation will then be compared to the results and functional status of previous patients who did not receive any type of combination intervention.

#### Timetable/Flowchart

The first and second weeks of implementation will include meeting with the unit managers and providing education to the bedside nurses who agreed to join the project. After educating the nurses, the first round of surveys will be given to the patients. The goal number of participants for this project is 100. The ratio of males to females admitted with a stroke is about 50%, so there will be approximately 50 males and 50 females participating. Since the neurological units do not house pediatric patients, the age will be adults 18 and over. After the initial PHQ-9 and Modified Rankin surveys are completed, the combination therapy can begin.

The combination interventions will begin in week three. At the end of week three, the patient will fill out another PHQ-9 survey to measure initial progress. Weeks four through six will be the maintenance weeks. This is the average length of stay for a stroke patient throughout the acute and rehabilitation phase. If patients are discharged home after four to six weeks, then these patients will receive a final discharge survey. Patients who require a longer rehabilitation stay will continue to receive the combination therapy and will fill out surveys again at six and eight weeks. Once all participants have been discharged home, follow-up phone calls will be made at 10 and 12 weeks to assess the patient's emotional and functional status, and the scales will be filled out using verbal information from these phone calls. See Appendix B for a detailed timeline flowchart.

#### **Data Collection Methods**

Data will be collected via Patient Health Questionnaire (PHQ-9) surveys and modified Rankin scores. These surveys and scores will be completed before implementation begins to collect baseline data. They will be completed periodically throughout the project and then again at the end of 12 weeks to collect final data (see Appendix C for the scoring instruments used). The PHQ-9 survey measures mood and emotional status. It scores the patient on nine domains from no depression symptoms at all to symptoms nearly every day. The modified Rankin scale measures the level of disability from zero to six, with zero being no disability and six being dead.

The patient population included in this project will be 100 total participants who have a diagnosis of a stroke (ischemic, hemorrhagic, subarachnoid). This will include approximately 50 males and 50 females over the age of 18, although it may not be feasible to have an exact 50/50 ratio of males to females. The goal is to have a mixed sample of different ethnicities which will be approximately 58% Non-Hispanic White and 42% Hispanic, Black, and other ethnicities

(University of Wisconsin Population Health Institute, 2023). This is the average patient population of the facility, but this exact diverse population may not be included since patients are admitted to the facility at random.

Data from the surveys and scales at the end of 12 weeks will be compared to the results of the pre-implementation surveys to see if there were improvements in scores. If the combination of interventions improved PHQ-9 and Modified Rankin scores, then these results will then be compared to the Modified Rankin score results of previous patients who did not receive any combination interventions, since every patient admitted with a stroke receives this score. This data will be collected using chart reviews and is readily available because these scores are part of the stroke documentation system. Since the project will be completed within a 12-week timeframe, data to compare from previous patients who did not receive interventions will be gathered from those admitted within 12 weeks before the project began.

A comprehensive sample of both males and females will be reviewed. The results of previous patients' modified Rankin scales will be placed in a spreadsheet. The final results of the patients who received the combination interventions will also be placed in a spreadsheet. The data of these two spreadsheets will be compared and analyzed using Excel analysis of variance (Digital Vidya, 2022). This method of data analysis will take the average of several columns of data, such as the Rankin Scores in this scenario. The two columns of Rankin Scores from the two samples will be run and analyzed by utilizing this variance, which will then equate the p-value. If the p-value of the project data is greater than 0.05, then that means there is a significant difference in the groups, and the project will be deemed successful. If the combination interventions were found to improve post-stroke patients' functionality and depression symptoms compared to the data gathered from chart reviews of patients who did not receive the

interventions, then a proposal will be made to the Neuro Institute director and Chief Nursing Officer about making the combination interventions a standard protocol for stroke treatment.

#### **Evaluation**

The results of the project will be evaluated by utilizing the Population Health Questionnaire (PHQ-9) Severity Measure for Depression as well as the Modified Rankin Scale to measure functionality before and after the project. The PHQ-9 survey will be given to patients who can fill out the questions or verbally give answers to the survey. This survey will be given at the beginning of the project, periodically throughout implementation, and again after 12 weeks. The Modified Rankin Scale will be completed by a nurse or physical therapist on admission and again after the patients' stay to measure the functional status of the patients. The PHQ-9 survey includes the following nine domains: loss of interest or pleasure in doing things, feeling down depressed, or hopeless, trouble sleeping, feeling tired, having poor appetite or overeating, feeling like a failure, trouble concentrating, moving or speaking slowly, thoughts of self-harm or suicide. The Modified Rankin Scale scores on a range of 0-6, with 0 being no physical dysfunction at all to 5 and 6 being severely disabled and bedridden to dead. The results of these surveys and scales will be compared at the beginning and end of implementation to see if the patients indicated improvement in emotional status and functionality throughout the project. The results of the patients who received the interventions will be evaluated against those who did not receive them by comparing the average discharge Modified Rankin scores. The current protocol is that every patient admitted with a diagnosis of a stroke receives a Modified Rankin score on admission and discharge to assess if they are making progress in their stroke recovery. A random sample of 100 previous patients' discharge scores will be gathered and compared to the average

discharge scores of those who did receive the combination interventions. See Appendix C for the survey and scale.

#### **Cost/Benefit Analysis**

The overall cost of the project will be low because staff and resources that are already available will be used. The surveys that will be used are online and free for public use. Data will be analyzed using a spreadsheet that the hospital already pays access to, and the facility already pays for the HealthStream education platform. Since the cognitive-behavioral interventions will be implemented by nursing staff, no additional staff will need to be hired.

Post-stroke depression greatly increases the cost of hospitalization. A study conducted in 2013 showed that post-stroke depression costs a facility 54% more on care than a patient who did not develop depression. Since that was 10 years ago, the cost is even more today. The increased cost is from a longer hospital stay, prolonged rehabilitation, and more outpatient visits after discharge (Husaini et al., 2013). According to Wijeratne & Sales (2021), it costs approximately \$58,000 a year for every patient who develops a stroke. Considering that depression more than doubles this cost, this means that post-stroke depression increases costs to over \$100,000 per patient. This is a significant amount of money not always reimbursed by insurance companies, and not every patient has health insurance. Because of this, the hospital may incur significant charges that do not receive reimbursement. The facility where this project will be implemented sees anywhere from 500-1000 stroke patients per year. According to the American Stroke Association (2022), one-third of all stroke patients will suffer from post-stroke depression. This means that if 33% of these patients suffer depression, this will increase hospitalization costs by \$8.5 million to \$15 million per year.

Not only does post-stroke depression significantly increase the cost of hospitalization, but it also increases morbidity and mortality, which leads to the facility having poor outcomes. Cai et al. (2019) and The American Stroke Association (2022) found that post-stroke depression is associated with a higher risk of another stroke reoccurring. Post-stroke depression also contributes to a greater prevalence of diabetes, hypertension, and coronary artery disease, which inadvertently increase the risk of having another stroke. Subsequently, the increase in comorbidities leads to increased rates of death and disability (American Stroke Association, 2022). Therefore, the benefit of implementing the project far outweighs the cost of a patient developing post-stroke depression.

#### **Discussion of Results**

When the proposed project is implemented, the expectation is that stroke patients' length of stay will begin to decrease, they will have better participation in physical therapy, their overall demeanor and outlook on life will improve, their length of stay will decrease, and the hospitalization costs will decrease. The goal is to see improvements in patients' post-discharge Modified Rankin and PHQ-9 scores. An improvement in these scores means that they will have a better prognosis and fewer functional disabilities. Implementation challenges will be maintaining the stakeholders' enthusiasm for change. They must share the vision for change and want to see the project take fruition. The leadership strategy that will be used for this project is transformational leadership. This inspires input from all parties involved and inspires stakeholders to share the same vision for change (Specchia et al., 2021). To sustain and manage the change, clear goals and expectations will be set, there will be a constant feedback loop between those involved in implementing the project, strong collaboration, and the team will feel

supported throughout. Ultimately, the end goal is to accomplish what is best for the patients and improve their overall quality of life.

#### Conclusions/Recommendations

The management of post-stroke depression using combination interventions to improve outcomes is recommended. An intervention such as the one discussed can help decrease post-stroke depression, improve quality of life, decrease length of stay, and increase hospital revenue. Since the bedside nurses will be the ones primarily involved with the project, the goal is to keep them enthusiastic and engaged without making them feel overwhelmed or overworked. Nurses are instrumental in implementing cognitive-behavioral exercises, and their involvement is critical to the project's success. For the future success of the project, it is recommended that the facility evaluate the current interventions for stroke patients and consider how this proposed project could make a difference in patients' lives. The leadership and nurses involved most with the patients must evaluate their feelings toward patient care and be cognizant of the fact that although change may be difficult initially, if successful, it has the potential to positively change many lives in the future.

#### References

- Ahrens, J., Shao, R., Blackport, D., Macaluso, D., Viana, R., Teasell, R. & Mehta, S. (2022). Cognitive-behavioral therapy for managing depressive and anxiety symptoms after a stroke: A systematic review and meta-analysis. *Topics in Stroke Rehabilitation*, 30(4), 368-383. https://doi.org/10.1080/10749357.2022.2049505
- American Stroke Association. (2022). *Let's talk about post-stroke depression*. <a href="https://www.stroke.org/">https://www.stroke.org/</a>-/media/Stroke-Files/Support-Group-Resources/Post-Stroke-Depression-Fact-Sheet.pdf
- Cai, W., Mueller, C., Li, Y.J., Shen, W.D. & Stewart, R. (2019). Post-stroke depression and risk of recurrence and mortality: A systematic review and meta-analysis. *Ageing Research Reviews*, 50(2019), 1568-1637. https://doi.org/10.1016/j.arr.2019.01.013
- Centers for Disease Control and Prevention. (2022, October 14). *Stroke Facts*.

  <a href="https://www.cdc.gov/stroke/facts">https://www.cdc.gov/stroke/facts</a>
- Christensen, B. (2022, June 10). *Modified Rankin Scale*. Medscape. https://emedicine.medscape.com/article/2172455-overview?form=fpf
- Cross, J.C., May, B.R., Mai, P.Q.M., Anderson, E., Welsh, C., Chandran, S., Chorath, K.T., Herr, S. & Gonzalez, D. (2023). A systematic review and evaluation of post-stroke depression clinical practice guidelines. *Journal of Stroke and Cerebrovascular Diseases*, 32(2023), 1-7. <a href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107292">https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107292</a>

riance),the%20means%20of%20different%20samples.

Desai, R. & Sonawane, K. (2019). Depression treatment use among stroke individuals with depression:

A cross-sectional analysis of the Medical Expenditure Panel Survey. *Research in Social and Administrative Pharmacy*, 15(2019), 1338-1343. <a href="https://doi.org/10.1016/j.sapharm.2018.11.009">https://doi.org/10.1016/j.sapharm.2018.11.009</a>

Digital Vidya (2022, April 28). Using Excel for statistical analysis: tips and techniques.

- https://www.digitalvidya.com/blog/using-excel-for-statisticalanalysis/#:~:text=any%20data%20set.,Using%20Excel%20for%20Statistical%20Analysis%3A%20ANOVA%20(Analysis%20of%20Va
- Haahr, A., Norlyk, A., Martinsen, B. & Dryer, P. (2019). Nurses experience of ethical dilemmas: A review. *Nursing Ethics*, 27(1), 258-272. https://doi.org/10.1177/0969733019832941
- Husaini, B., Levine, R., Sharp, L., Cain, V., Novotny, M., Hull, P., Orum, G., Samad, Z., Sampson, U. & Moonis, M. (2013). Depression increases hospitalization cost: An analysis of 17,010 stroke patients in 2008 by race and gender. *Stroke Research and Treatment*, 2013(846732), 1-8. <a href="https://doi.org/10.1155/2013/846732">https://doi.org/10.1155/2013/846732</a>
- Lavu, V.K., Mohamed, R.A., Huang, R., Potla, S., Bhalla, S., Al Qabandi, Y., Nandula, S.A., Boddepalli, C.S., Gutlapalli, S.D., & Mohammed, L. (2022). Evaluation and Treatment of Depression in Stroke Patients: A Systematic Review. *Cureus*, 14(8), e28137. <a href="https://doi.org/10.7759/cureus.28137">https://doi.org/10.7759/cureus.28137</a>
- Lee, Y., Chen, B., Fong, M.W.M., Lee, J.M., Nicol, G.E., Lenze, E.J., Connor, L.T., Baum, C. & Wong, A.W.K. (2020). Effectiveness of non-pharmacological interventions for treat post-stroke depressive symptoms: systematic review and meta-analysis of randomized control trials. *Topics in Stroke Rehabilitation*, 28(4), 289-320. <a href="https://doi.org/10.1080/10749357.2020.1803583">https://doi.org/10.1080/10749357.2020.1803583</a>

- Medeiros, G.C., Roy, D., Kontos, N. & Beach, S.R. (2020). Post-stroke depression: A 2020 updated review. *General Hospital Psychiatry*, 66(2020), 70-80. https://doi.org/10.1016/j.genhosppsych.2020.06.011
- Modified Rankin Scale (2022). Medscape. <a href="https://reference.medscape.com/calculator/152/modified-rankin-scale-mrs">https://reference.medscape.com/calculator/152/modified-rankin-scale-mrs</a>
- Office for Human Research Protections (2018). *Human Subject Regulations Decision Charts: 2018*\*Requirements. The University of Rhode Island. <a href="https://web.uri.edu/wp-content/uploads/sites/922/Human-Subject-Regulations-Decision-Charts-2018-Requirements.pdf">https://web.uri.edu/wp-content/uploads/sites/922/Human-Subject-Regulations-Decision-Charts-2018-Requirements.pdf</a>
- Pfizer to offer free public access to mental health assessment tools to improve diagnosis and patient care. (2010, July 21). Pfizer. Retrieved March 6, 2024, from <a href="https://www.pfizer.com/news/press-release/press-release-">https://www.pfizer.com/news/press-release-</a> detail/pfizer\_to\_offer\_free\_public\_access\_to\_mental\_health\_assessment\_tools\_to\_improve\_diag nosis\_and\_patient\_care
- Sarkar, A., Sarmah, D., Datta, A., Kaur, H., Jagtap, P., Raut, S., Shah, B., Singh, U., Baidya, F., Bohra, M., Kalia, K., Borah, A., Wang, X., Dave, K.R., Yavagal, D.R. & Bhattacharya, P. (2021). Post-stroke depression: Chaos to exposition. *Brain Research Bulletin*, *168*(2021), 74-88. <a href="https://doi.org/10.1016/j.brainresbull.2020.12.012">https://doi.org/10.1016/j.brainresbull.2020.12.012</a>
- Specchia, M.L., Cozzolino, M.R., Carini, E., Di Pilla, A., Galletti, C., Ricciardi, W. & Damiani, G. (2021). Leadership styles and nurses' job satisfaction. Results of a systematic review. *International Journal of Environmental Research and Public Health*, 18(4), 1-15. https://doi.org/10.3390/ijerph18041552
- Starkstein, S.E. & Hayhow, B.D. (2019). Treatment of post-stroke depression. *Current Treatment Options Neurology*, 21(31), 1-10. <a href="https://doi.org/10.1007/s11940-019-0570-5">https://doi.org/10.1007/s11940-019-0570-5</a>

- Tao, S., Geng, Y., Li, M., Ye, J. & Liu, Z. (2022). Effectiveness of mindfulness-based stress reduction and mindfulness-based cognitive therapy on depression in poststroke patients A systematic review and meta-analysis of randomized control trials. *Journal of Psychosomatic Research*, 163(2022), 1-11. https://doi.org/10.1016/j.jpsychores.2022.111071
- University of Wisconsin Population Health Institute. (2023). Explore Health Rankings. County Health Rankings and Roadmaps (Smith County, Texas). <a href="https://www.countyhealthrankings.org/explore-health-rankings/texas/smith?year=2023">https://www.countyhealthrankings.org/explore-health-rankings/texas/smith?year=2023</a>
- U.S. News and World Report. (2023). *UT Health Tyler stroke*. U.S. News High Performing Hospitals. <a href="https://health.usnews.com/best-hospitals/area/tx/east-texas-medical-center-6740092/stroke">https://health.usnews.com/best-hospitals/area/tx/east-texas-medical-center-6740092/stroke</a>
- Van Nimwegen, D., Hjelle, E.G., Bragstad, L.K., Kirkevold, M., Sveen, U., Hafsteinsdottir, T., Schoonhoven, L., Visser-Meily, J. & Man-van Ginkel, J.M. (2023). Interventions for improving psychosocial wellbeing after stroke: A systematic review. *International Journal of Nursing Studies*, 142(2023), 1-23. https://doi.org/10.1016/j.ijnurstu.2023.104492
- Wijeratne, T. & Sales, C. (2021). Understanding why post-stroke depression may be the norm rather than the exception: The anatomical and neuroinflammatory correlates of post-stroke depression.

  \*Journal of Clinical Medicine, 10(1674), 1-21. https://doi.org/10.3390/jcm10081674
- Withers, H., Plumley-Jones, J., Pyatt, E., Williams, L., Yule, L. & Kyte, D. (2021). The effectiveness of cognitive behavioral therapy versus antidepressants for treatment of post-stroke depression in adults. *The British Student Doctor*, *5*(1), 5-17. https://doi.org/10.18573/bsdj.169
- Xie, J., Geng, X., Fengcheng, F., Fu, X., He, S. & Li, T. (2022). The efficacy of therapies for post-stroke depression in aging: an umbrella review. *Frontiers in Aging Neuroscience*, *14*(993250), 1-9. https://doi.org/10.3389/fnagi.2022.993250

# Appendix A

#### **Evidence Table**

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
1.Ahren s, J.,	NA	Syste matic	Medline, EMBR,	IV1: CBT	HADS	SMD	Overall effects of CBT:	Strengths: high LOE, answers
Shao,		Revie	Cochrane	IV2:	BDI	SE	• SMD +/- SE:	PICOT question
R., Blackpo rt, D., Macalus o, D., Viana, R., Teasell, R. & Mehta, S. (2022).		w and Meta- analy sis	& PsychIN FO searched. 9 studies with 672 participa nts included in the study.	antidepres sants DV: PSD	BAI Wakefield Depression Inventory CES-D	p-value	0.95 +/- 0.22 • p<.000  After 3-months: • SMD +/- SE: 0.622 +/- 0.285 • p<.029	Limitations: small sample, limited comparison, lack of adequate follow-up  Feasibility: feasible  Risk of harm: low  Level of evidence: 1  Quality of Evidence: medium

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Cognitiv			563					USPSTF grade: B
e-			results;					
behavior			563 after					Recommendation: Good results
al			deuplicat					of CBT on PSD in 3-month
therapy			es					follow-up. Better outcomes in
for			removed;					combination with
managin			507					antidepressants. Results are good
g			removed					despite limitations.
depressi			after					despite initiations.
ve and			screen;					
anxiety			56 full-					
sympto			text					
ms after			assessed;					
a stroke:			47 more					
a			excluded;					
systemat			9					
ic			included					
review			in final					
and			yield.					

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
meta-			Articles					
analysis.			excluded					
			if they					
			did not					
			meet					
			criteria: CBT					
			interventi					
			on; stroke					
			= 3</td <td></td> <td></td> <td></td> <td></td> <td></td>					
			months					
			prior; 18					
			years old;					
			focus of					
			CBT was					
			anxiety					
			Or depressio					
			depressio					
			n					

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
2. Byun, E., Becker, K.J., Kohen, R., Kirkness , C.J., & Mitchell , P.H. (2021). Brief psychos ocial intervent ion to	NA	Rand omize d Contr ol Trial	Sample: Screened (n=314) Met criteria (n=133) Consente d (n=100) TPT (n=37) IPT (n=35) UC (n=28)	IV: CBT for PSD  DV1: Fatigue  DV2: SLD  DV3: WD	P-value	ICC CI	Fatigue:  • w/i p=.042; btwn p=.394 SLD:  • w/i p = .024; btwn p = .102 WD:  • w/i p = .004; btwn p = .508	Strengths: High LOE, good sample size, results measured 8wks, 21wks & 1yr, supports nursing interventions to answer PICOT  Limitations: Sample from one region, small population  Feasibility: Feasible: nurses can do intervention, especially in rehab setting  Risk of harm: none

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
address poststro ke depressi on may also benefit fatigue and sleep- wake disturba nce.			Setting: Home/Re habilitati on hospital					Level of evidence: II  Quality of Evidence: medium  USPSTF grade: B  Recommendation: CBT can be done by RN, especially in a rehab setting in conjunction with or without antidepressants.
3. Cross, J.C., May, B.R., Mai, P.Q.M.,	NA	Syste matic Litera ture	Sample: 1236 screened; 27 considere d; 7 met	IV1: Psychothe rapy IV2: PCT	AGREE II Instrument on 6 domains	ICC CI	Domain 1 (scope & purpose)  • ICC: 0.827  • 95% CI  0.444<0.967	Strengths: High LOE, recommendations answer PICOT Limitations: Small sample size

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Anderso n, E., Welsh, C., Chandra n, S., Chorath, K.T., Herr, S. & Gonzale z, D. (2023). A systemat ic review and evaluati		Revie	inclusion criteria Setting: literature review across three databases (Pubmed, CINAHL , SCOPUS ) & Google search	DV: PSD	Likert Scale		Domain 2 (stakeholder involvement) • ICC: 0.95 • 95% CI	Feasibility: feasible – findings from guidelines could be applied to facility  Risk of harm: low  Level of Evidence: IV  Quality of Evidence: medium  USPSTF grade: B  Recommendation: Identifying depression early & treating with CBT and antidepressants should be in the guidelines.

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
on of post-stroke depressi on clinical practice guidelin es							<ul> <li>0.874</li> <li>95% CI</li> <li>0.593&lt;0.976</li> <li>Domain 6</li> <li>(editorial independence)</li> <li>95% CI</li> <li>0.427&lt;0.966</li> </ul>	
4. Desai, R. & Sonawa ne, K. (2019). Depressi on treatmen t use among	NA	Cross - Secti onal Surve y	Sample: 759 people >18 years old who had a diagnosis of stroke/de	IV 1: AND only IV 2: AND & Psychothe rapy DV: PSD	PDC ratio Student's t- test Multinomial logistic regression analysis	OR CI PDC	AND only  OR: 1.56  95% CI: 1.012-2.391  PDC: 57.6 +/- 3.74  AND & CBT  OR: 2.32  95% CI: 1.288-4.175	Strengths: Answers PICOT question, large sample size  Limitations: some unreliable self-reporting, missing data, low number of patients reported using combination therapy

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
stroke			pression				PDC: 65.8 +/-	Feasibility: feasible – findings
individu			surveyed				6.89	support the need for CBT
als with depressi on: A			Setting:					Risk of harm: none
cross-			in-person interview					Level of Evidence: III
sectional analysis of the			interview					Quality of Evidence: medium
Medical								USPSTF grade: B
Expendi ture Panel Survey.								Recommendation: Although low number used combination therapy, it is more effective in
								those who reported use of both.
5. Lee, Y.,	NA	SR & MA	Database s	IV 1: MBSR	Cochrane Collaborativ	SMD	• SMD: -1.27 • 95% CI (-	Strengths: Highest LOE, answers PICOT
Chen,			screened:			CI	1.71 to -0.84)	

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
В.,		of	MEDLIN	IV 2:	e Review		• $P = < 0.001$	Limitations: Small sample,
Fong,		RCTs	E,	MBCT	Manager	P-value		variability across studies
M.W.M.			CINAHL		Cochrane's			Feasibility: feasible – findings
, Lee,			,	DV: PSD	Q Test			support positive result with CBT
J.M.,			Cochrane					
Nicol,			. Scopus,		HAMD			Risk of harm: none
G.E.,			Library,		CES-D			
Lenze,			Informati					Level of evidence: I
E.J.,			on		GDS			
Connor,			Science					Quality of evidence: medium
L.T.,			and		SDS			
Baum,			Technolo					USPSTF grade: B
C. &			gy		CPRS			
Wong,								Recommendation: CBT should
A.W.K.			Abstracts					not replace antidepressants and
(2020).			found					should be used in combination.
Effectiv			(n=1703					More research needed to support
eness of								the combination of both.
non-								

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
pharmac			Duplicate					
ological			s (n=933)					
intervent								
ions for			Excluded					
treat			(n=660)					
post-								
stroke			Excluded					
depressi			again					
ve			(n=25)					
sympto			ard					
ms:			3 <sup>rd</sup>					
systemat			exclusion					
ic			(n=6)					
review			المام ما ما					
and meta-			included in MA					
analysis			in MA (n=22)					
of			(11–22)					
randomi								

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
zed								
control trials.								
6.	NA	Narra	PubMed,	IV1:	DSM-5 for	Mean	Combination	Strengths: answers PICOT
Medeiro		tive	Medline,	combinati	depression		treatment	question, large sample
s, G.C.,		revie	Embase,	on		CI	• Mean: -0.95	
Roy, D.,		W	Google	treatment			• 95% CI -1.20	Limitations: low LOE
Kontos,			Scholar			p-value	to -0.71	
N. &			searched	IV2:			• P < 0.00001	Feasibility: feasible
Beach,				antidepres		OR	Antidepressants	
S.R.			140	sants			alone	Risk of harm: none
(2020).			articles	alone			• $OR = 0.34$	
Post-			reviewed				• 95% CI =	Level of Evidence V
stroke				IV3: CBT			0.22-0.53	Quality of evidence: medium
depressi				alone			• P < 0.001	LIGDOTT I D
on: A				DM DGD			CBT alone	USPSTF grade: B
2020				DV: PSD			• Mean = -0.76	December 1
updated							• 95% CI = -	Recommendation: Studies show
review.							1.22 to -0.29	a positive effect of treating PSD

Citation : (i.e., author(s), date				Major Variables Studied				
of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	and Their Definition	Measureme nt of Major Variables	Data Analysi	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
titie)	UIK	ou	Setting	S	variables	S	P = 0.001	with both antidepressants and
							2 0.001	CBT.

7.	NA	Syste	Google	IV1: PCT	ZDS	Narrati	A combination of	Strengths: Helps answer PICOT,
Sarkar,		matic	Scholar,			ve	CBT & PCT	large sample
A.,		revie	Cochrane	IV2: CBT	HDRS	review	showed	
Sarmah,		w	, Springer			only	promising	Limitations: No quantifiable
D.,		W	Online,	DV: PSD	BDI-II	that	improvement in	measurements used for results,
Datta,			PubMed			measur	PSD	international study, low LOE
A.,			reviewed		MES	ed		
Kaur,						improv		Feasibility: feasible with more
Н.,			300		HADS	ement		research to support
Jagtap,			articles			on		
P., Raut,			reviewed		MADRS	depress		Risk of harm: none
S., Shah,						ion		
В.,					MMSE	rating		LOE: V
Singh,						scales		
U.,					CES-D			Quality of evidence: medium
Baidya,								
F.,					D-VAMS			USPSTF grade: B
Bohra,								
M.,					PHQ-9			Recommendations:
Kalia,								Antidepressants are effective for
K.,					TICS-M			preventing & treating PSD but
Borah,								may cause rebound depression.
A.,								CBT shows positive effects as an
Wang,								additional treatment strategy.
X.,								Need more evidence to support
Dave,								combination therapy.
K.R.,								

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Yavagal								
, D.R. &								
Bhattach								
arya, P.								
(2021).								
Post-								
stroke								
depressi on: Caos								
to								
expositi								
on								
8.	NA	SR	PCT:12	IV 1:	HAM-D	OR	AND remission	Strengths: highest LOE,
Starkstei	1,12	and	RCTs,	AND		011	of PSD:	compares CBT and
n, S.E.		MA	then 49	IV2:	TESS	CI	• OR = 0.47	antidepressants, large sample
&		of	RCTs,	Psychothe	HDRS		• 95% CI; 0.22-	Limitations: differences in
Hayhow		RCTs	then 20	rapy			0.98	studies, efficacy of treatment
, B.D.		To	studies		valid scales		50% reduction on	
(2019).		assess		DV: PSD	measure		scales	

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Treatme		treat	Psychoth		efficacy of		• OR = 0.22	Feasibility: Feasible, large
nt of		ments	erapy: 12		therapy		• 95% CI; 0.09-	sample, multiple therapies
post-		for	studies,		before/after		0.52	
stroke		PSD:	then 23				Psychotherapy:	Risk of harm: low
depressi		AND,	RCTs,				• OR=10	
on.		CBT	then 7				95% CI; 1.44-	Level of evidence: I
			studies				69.2	
			0 700					Quality of Evidence: high
			Over 700					LICEOTE I D
			studies reviewed.					USPSTF grade: B
			reviewed.					Recommendations:
								antidepressants and
								psychotherapy such as CBT
								should be first-line treatment.
9. Tao,	NA	SR	PubMed,	IV1:	Cochrane	SMD	Effect on	Strengths: highest LOE,
S.,		and	CINAL,	MBCT	Collaboratio		Depression	evaluates CBT &
Geng,		MA	Web of		n Bias Tool	CI	• $SMD = -0.93$	antidepressants, answers PICOT
Y., Li,			Science,					_

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
M., Ye,		of	Embase,	IV2:	GRADE	p-value	• 95% CI -1.34	Limitations: international study,
J. & Liu,		RCTs	Cochrane	MBSR	system		to -0.53	some small studies in review,
Z.			, CNKI,				• P < 0.001	MBCT recommended as adjunct
(2022).			Wangfan	DV: PSD	Cochrane		Effect on	therapy, adverse events not
Effectiv			g		Collaborativ		depressive	evaluated
eness of			databases		e Review		emotions	
mindful			searched		manager		$\bullet  SMD = -0.46$	Feasibility: Feasible
ness-			7 trials		Cochrane's		• 95% CI -1.71	
based			and 500		Q test		to -0.84	Risk of harm: low
stress reductio n and			participa nts studied		Higgin's convention		P <0.001	Level of evidence: I
mindful			3000100					Quality of Evidence: medium
ness-			192		HAMD			Quality of Exturious interiors
based			articles					USPSTF grade: B
cognitiv			found; 65		CES-D			6
e			removed					Recommendations: studies show
therapy			for		CPRS			a positive effect of combination
on			duplicate					therapy with antidepressants &

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
depressi on in poststro ke patients - A systemat ic review and meta- analysis of randomi zed control trials.			s; 32 excluded again; 6 removed for lack of text; 82 removed for being insufficie nt; final number included = 7		GDS SDS			CBT. MBCT can be added to treatment. Support with more research.

10. Van	NA	SR	Pubmed,	IV:	BDI	p-value	Some studies	Strengths: large sample, study
Nimweg		and	Embase,	cognitive			report	that measures nursing-specific
en, D.,		data	PsychIN	therapy	CES-D		improvements in	interventions, answers PICOT
Hjelle,		synth	FO,				depression with	
E.G.,		esis	CINAHL	DV: PSD	GDS		cognitive	Limitations: international study,
Bragstad		of	,				behavioral	some studies lack results
, L.K.,		RCTs	Cochrane		HADS		training with	
Kirkevol		and	library				nursing. Some	Feasibility: Feasible, nursing
d, M.,		quasi-	searched		HAMD		results may	driven
Sveen,		exper					include	
U.,		iment	18,608		PROMIS		antidepressants	Risk of harm: none
Hafstein		al	found;					
sdottir,		studie	after		SDS		p-values include	Level of evidence: III
T.,		S	duplicate				different nursing	
Schoonh			S				specialties	Quality of Evidence: medium
oven, L.,			removed				implementing	
Visser-			9,088;				CBT	USPSTF grade: B
Meily, J.			after					
& Man-			title/abstr				P=0.03	Recommendations: There are
van			act screen				P=0.002	CBT interventions nurses can
Ginkel,			246; full				P=0.048	implement & are effective in
J.M.			text				P=0.023	reducing PSD. Can be done with
(2023).			screen					or without antidepressants.
Interven			93;					
tions for			quality					
improvi			assessme					
ng			nt 33;					

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
psychos			final					
ocial			yield 60					
wellbein g after			60					
stroke:			studies					
A			included;					
systemat			52 RCTs;					
ic			3 non-					
review.			RCTs; 4					
			quasi-					
			experime					
			ntal; 1 randomiz					
			ed cross-					
			over.					
11.	NA	SR of	MEDLIN	IV1: CBT	HAM-D	P-value	CBT alone:	Strengths: highest LOE, strong
Withers,		RCTs	Ε,				• 95% CI -0.76	answer to PICOT
H.,			Pubmed,	IV2: AND	MES	CI	[-1.22 to -	
Plumble			Cochrane				0.29]	


Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
y-Jones,			,	DV: PSD	QM		• P=0.001	Limitations: small sample size,
J., Pyatt,			PsychIN				CBT w/AND	support w/more evidence
E.,			FO		Jadad		• 95% CI -	
William					CRBT		0.95[-1.20 to -	Feasibility: Feasible
s, L.,			(n=162);				0.71]	
Yule, L.			Duplicate				• P=<0.0001	Risk of harm: low
& Kyte,			S				CBT w/some	
D.			removed				AND	Level of evidence: I
(2021).			(n=40);				• 95% CI -	
The			After				0.20[-0.53 to	Quality of Evidence: high
effective			duplicate				0.13]	Habame 1 b
ness of			S				• P=no p-value	USPSTF grade: B
cognitiv			(n=122);				noted	
e			Title/abst				Overall	Recommendations: Combination
behavior			ract				• 95% CI -	therapy is likely to be effective
al			rejected				0.83[-1.05 to -	for PSD. Support findings with more evidence.
therapy			(n=106); After				0.60]	more evidence.
versus							P=<0.001	
antidepr			screen					

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition s	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
essants			(n=16);					
for			After					
treatmen			full-text					
t of			screen					
post-			(n=5);					
stroke			Final					
depressi			yield for					
on in			SR					
adults.	37.4	G.D.	(n=5)	TV 1 CDT	114345	C) (D)	AND	
12. Xie,	NA	SR	Sample:	IV 1: CBT	HAMD	SMD/	AND	Strengths: Strengths: high LOE,
J., Geng,		and	-17		NILLOC	MD	• Escitalopram:	compares therapies, answers
X.,		MA of	studies,	IV 2:	NIHSS	RR/OR	SMD: -2.72,	PICOT
Fangche ng, F.,		RCTs	including 267 trials	AND	ADL	KK/OK	95% CI -3.61 to -1.82	Limitations: small treatment
Fu, X.,		IXC18	201 utals		ADL	CI	• Paroxetine:	size, international study
He, S. &			Pubmed/				MD: -9.79,	Size, international study
Li, T.			Web of				95% CI –	Feasibility: Feasible
(2022).			Science				16.94 to -2.64	1 Casionity . 1 Casion
The							10.54 to 2.04	Risk of harm: low

publicat	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
efficacy of therapie s for post- stroke depressi on in aging: an umbrella review.			Screened (n=291); Excluded (n=255); Excluded again (n=36); Included (n=17) Inclusion : peer-reviewed, English, MA/SR, general population				• Citalopram: MD: -0.43, 95% CI – 0.85 to -0.01 CBT SMD: -0.76, 95% CI -1.22 to -0.29	Level of evidence: I  Quality of Evidence: medium  USPSTF grade: B  Recommendations: CBT may be an effective treatment strategy for PSD & results were better than patients who received just antidepressants.

Citation : (i.e., author( s), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
			Exclusio					
			n: duplicate					
			s, unpublish					
			ed, not					
			English,					
			insufficie nt details					

Used with permission, © 2007 Fineout-Overholt



# Appendix C

## **Instrument**

#### PATIENT HEALTH QUESTIONNAIRE (PHQ-9)

ID #:		DATE:		
Over the last 2 weeks, how often have you been				
bothered by any of the following problems? (use "√" to indicate your answer)	Not at all	Several days	More than half the days	Nearly every day
1. Little interest or pleasure in doing things	0	1	2	3
2. Feeling down, depressed, or hopeless	0	1	2	3
3. Trouble falling or staying asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having little energy	0	1	2	3
5. Poor appetite or overeating	0	1	2	3
6. Feeling bad about yourself—or that you are a failure or have let yourself or your family down	0	1	2	3
7. Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
8. Moving or speaking so slowly that other people could have noticed. Or the opposite — being so figety or restless that you have been moving around a lot more than usual	0	1	2	3
Thoughts that you would be better off dead, or of hurting yourself	0	1	2	3
	add columns		+	+
(Healthcare professional: For interpretation of TOT) please refer to accompanying scoring card).	AL, TOTAL:			
10. If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?		Som ew	cult at all hat difficult ficult	

Copyright © 1999 Pfizer Inc. All rights reserved. Reproduced with permission. PRIME-MD© is a trademark of Pfizer Inc. A2663B 10-04-2005

The PHQ-9 is a public domain measure and can be reproduced without permission (Pfizer, 2010).

### PHQ-9 Patient Depression Questionnaire

#### For initial diagnosis:

- Patient completes PHQ-9 Quick Depression Assessment.

#### Consider Major Depressive Disorder

#### Consider Other Depressive Disorder

- if there are 2-4 √s in the shaded section (one of which corresponds to Question #1 or #2)

Note: Since the questionnaire relies on patient self-report, all responses should be verified by the clinician, and a definitive diagnosis is made on clinical grounds taking into account how well the patient understood the questionnaire, as well as other relevant information from the patient.

Diagnoses of Major Depressive Disorder or Other Depressive Disorder also require impairment of social, occupational, or other important areas of functioning (Question #10) and ruling out normal bereavement, a history of a Manic Episode (Bipolar Disorder), and a physical disorder, medication, or other drug as the biological cause of the depressive symptoms.

# To monitor severity over time for newly diagnosed patients or patients in current treatment for depression:

- Patients may complete questionnaires at baseline and at regular intervals (eg, every 2 weeks) at home and bring them in at their next appointment for scoring or they may complete the questionnaire during each scheduled appointment.
- 3. Add together column scores to get a TOTAL score.
- Refer to the accompanying PHQ-9 Scoring Box to interpret the TOTAL score.
- Results may be included in patient files to assist you in setting up a treatment goal, determining degree of response, as well as guiding treatment intervention.

#### Scoring: add up all checked boxes on PHQ-9

For every ✓ Not at all = 0; Several days = 1; More than half the days = 2; Nearly every day = 3

#### Interpretation of Total Score

Total Score	Depression Severity
1-4	Minimal depression
5-9	Mild depression
10-14	Moderate depression
15-19	Moderately severe depression
20-27	Severe depression

Copyright © 1999 Pfizer Inc. All rights reserved. Reproduced with permission. PRIME-MD© is a trademark of Pfizer Inc. A2663B 10-04-2005

The PHQ-9 is a public domain measure and can be used without permission (Pfizer, 2010).

mRS Score	Description
0	No symptoms at all
1	No significant disability despite symptoms; able to perform all usual duties and activities.
2	Slight disability; Unable to perform all previous activities but able to look after own affairs without assistance.
3	Moderate disability; requires some help, but able to walk without assistance.
4	Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.
5	Severe disability; bedridden, incontinent, and requires nursing care and attention.
6	Dead

Modified Rankin Scale (2022). Medscape.